Boardroom Alpha
Boardroom Alpha
WGRX · Amended Current Report (Form 8-K/A) · Filed June 2, 2026

Wellgistics Health Inc — Amended Current Report (Form 8-K/A)

Form
8-K/A
Filed
June 2, 2026
Period
May 27, 2026
Ticker
WGRX
Accession
0001493152-26-026879
Boardroom Alpha · Filing insights

Amendment furnishes previously omitted exhibits—Placement Agent Warrant and May 27, 2026 press release—without other changes.

About Wellgistics Health Inc
Market cap
$100K
1Y TSR
−93.3%
Board grade
D
Sector
Consumer Defensive
CEO
Gerald Commissiong
Last annual meeting: May 21, 2026 · View full Wellgistics Health Inc profile →

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

Amendment No. 1

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 27, 2026

 

WELLGISTICS HEALTH, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-42530   93-3264234

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3000 Bayport Drive

Suite 950

Tampa, FL

  33607
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (844) 203-6092

 

Not Applicable

(Former name or former address, if changed since last report)

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   WGRX   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act of 1933 or Rule 12b-2 under the Securities Exchange Act of 1934.

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 
 

 

Explanatory Note

 

This Amendment No. 1 to Current Report on Form 8-K (this “Amendment”) amends the Current Report on Form 8-K filed by Wellgistics Health, Inc. (the “Company”) on May 29, 2026 (the “Original Report”). The sole purpose of this Amendment is to furnish Exhibit 4.3 and Exhibit 99.1, which were inadvertently omitted in the Original Report. Other than as described above, this Amendment does not modify or update any disclosures in or exhibits to the Original Report nor does it reflect any events that may have occurred subsequent to the Original Report.

 

 
 

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
4.3   Form of Placement Agent Warrant.
99.1   Press Release issued by Wellgistics Health, Inc. on May 27, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 2, 2026 WELLGISTICS HEALTH, INC.
     
  By: /s/ Prashant Patel
  Name: Prashant Patel
  Title: Chief Executive Officer

 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Wellgistics Health Inc (WGRX)

Reference

Frequently asked questions

When did Wellgistics Health Inc file this 8-K/A?
Wellgistics Health Inc (WGRX) filed this Amended Current Report (Form 8-K/A) with the SEC on June 2, 2026. The accession number assigned by EDGAR is 0001493152-26-026879.
What does an 8-K/A disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Amendment furnishes previously omitted exhibits—Placement Agent Warrant and May 27, 2026 press release—without other changes. This is Boardroom Alpha's one-line summary of the amended current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Wellgistics Health Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K/A Wellgistics Health Inc has filed under CIK 2030763, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer